• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

俄罗斯免疫规划中使用的灭活流感疫苗在小鼠中的比较免疫学研究

Comparative Immunological Study in Mice of Inactivated Influenza Vaccines Used in the Russian Immunization Program.

作者信息

Shanko Andrei, Shuklina Marina, Kovaleva Anna, Zabrodskaya Yana, Vidyaeva Inna, Shaldzhyan Aram, Fadeev Artem, Korotkov Alexander, Zaitceva Marina, Stepanova Liudmila, Tsybalova Liudmila, Kordyukova Larisa, Katlinski Anton

机构信息

Research and Development Department, FORT LLC, 119435 Moscow, Russia.

N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ivanovsky Institute of Virology, 123098 Moscow, Russia.

出版信息

Vaccines (Basel). 2020 Dec 12;8(4):756. doi: 10.3390/vaccines8040756.

DOI:10.3390/vaccines8040756
PMID:33322762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7768547/
Abstract

A series of commercial inactivated influenza vaccines (IIVs) used in the Russian National Immunization Program were characterized to evaluate their protective properties on an animal model. Standard methods for quantifying immune response, such as hemagglutination inhibition (HAI) assay and virus neutralization (VN) assay, allowed us to distinguish the immunogenic effect of various IIVs from that of placebo. However, these standard approaches are not suitable to determine the role of various vaccine components in immune response maturation. The expanded methodological base including an enzyme-linked immunosorbent assay (ELISA) and a neuraminidase ELISA (NA-ELISA) helped us to get wider characteristics and identify the effectiveness of various commercial vaccines depending on the antigen content. Investigations conducted showed that among the IIVs tested, Ultrix Ultrix Quadri and VAXIGRIP elicit the most balanced immune response, including a good NA response. For Ultrix, Ultrix Quadri, and SOVIGRIPP (FORT LLC), the whole-virus specific antibody subclass IgG1, measured in ELISA, seriously prevailed over IgG2a, while, for VAXIGRIP and SOVIGRIPP (NPO Microgen JSC) preparations, the calculated IgG1/IgG2a ratio was close to 1. So, the immune response varied drastically across different commercial IIVs injected in mice.

摘要

对俄罗斯国家免疫规划中使用的一系列商业化灭活流感疫苗（IIV）进行了特性分析，以评估其在动物模型上的保护特性。用于量化免疫反应的标准方法，如血凝抑制（HAI）试验和病毒中和（VN）试验，使我们能够区分各种IIV与安慰剂的免疫原性效果。然而，这些标准方法并不适合确定各种疫苗成分在免疫反应成熟过程中的作用。包括酶联免疫吸附测定（ELISA）和神经氨酸酶ELISA（NA-ELISA）在内的扩展方法基础，帮助我们获得了更广泛的特性，并根据抗原含量确定了各种商业化疫苗的有效性。所进行的研究表明，在测试的IIV中，Ultrix Ultrix Quadri和VAXIGRIP引发的免疫反应最为平衡，包括良好的NA反应。对于Ultrix、Ultrix Quadri和SOVIGRIPP（FORT LLC），在ELISA中测量的全病毒特异性抗体亚类IgG1显著高于IgG2a，而对于VAXIGRIP和SOVIGRIPP（NPO Microgen JSC）制剂，计算出的IgG1/Igg2a比值接近1。因此，在小鼠中注射的不同商业化IIV的免疫反应差异很大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/5df6dc145d96/vaccines-08-00756-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/39042a03398c/vaccines-08-00756-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/9778ddd1a4b4/vaccines-08-00756-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/9045454feafa/vaccines-08-00756-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/bbc626d19dad/vaccines-08-00756-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/eaae48a07be3/vaccines-08-00756-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/36cb19f3106f/vaccines-08-00756-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/cae8ff1f7996/vaccines-08-00756-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/5df6dc145d96/vaccines-08-00756-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/39042a03398c/vaccines-08-00756-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/9778ddd1a4b4/vaccines-08-00756-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/9045454feafa/vaccines-08-00756-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/bbc626d19dad/vaccines-08-00756-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/eaae48a07be3/vaccines-08-00756-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/36cb19f3106f/vaccines-08-00756-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/cae8ff1f7996/vaccines-08-00756-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ae7/7768547/5df6dc145d96/vaccines-08-00756-g008.jpg

相似文献

1
Comparative Immunological Study in Mice of Inactivated Influenza Vaccines Used in the Russian Immunization Program.俄罗斯免疫规划中使用的灭活流感疫苗在小鼠中的比较免疫学研究
Vaccines (Basel). 2020 Dec 12;8(4):756. doi: 10.3390/vaccines8040756.
2
Characterization of Inactivated Influenza Vaccines Used in the Russian National Immunization Program.俄罗斯国家免疫规划中使用的灭活流感疫苗的特性
Vaccines (Basel). 2020 Aug 30;8(3):488. doi: 10.3390/vaccines8030488.
3
Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.灭活H7流感病毒疫苗尽管仅诱导产生低水平的中和抗体，但仍可保护小鼠。
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.
4
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.抗流感病毒神经氨酸酶抗体：保护作用的独立相关因素。
J Infect Dis. 2015 Oct 15;212(8):1191-9. doi: 10.1093/infdis/jiv195. Epub 2015 Apr 8.
5
Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.用重组杆状病毒产生的甲型流感病毒血凝素和神经氨酸酶进行免疫接种，可产生比传统疫苗更平衡、更广泛的免疫反应。
Vaccine. 1999 Apr 9;17(15-16):2073-80. doi: 10.1016/s0264-410x(98)00413-7.
6
VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.VaxArray 用于流感疫苗血凝素和神经氨酸酶效力检测。
Vaccine. 2018 May 17;36(21):2937-2945. doi: 10.1016/j.vaccine.2018.04.048. Epub 2018 Apr 23.
7
The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly.单独及联合接种活流感疫苗和灭活流感疫苗后，年轻成年人及老年人的体液免疫反应。
J Clin Virol. 2002 Apr;24(3):193-201. doi: 10.1016/s1386-6532(01)00246-3.
8
An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.改进的具有增强交叉保护作用的灭活流感疫苗。
Front Immunol. 2018 Aug 9;9:1815. doi: 10.3389/fimmu.2018.01815. eCollection 2018.
9
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.神经氨酸酶抑制抗体滴度与对同一神经氨酸酶亚型的异源流感病毒株的保护作用相关。
J Virol. 2018 Aug 16;92(17). doi: 10.1128/JVI.01006-18. Print 2018 Sep 1.
10
A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses.一种实用的流感中和测定法，可同时定量检测血凝素和神经氨酸酶抑制抗体反应。
Vaccine. 2010 Jan 8;28(3):790-7. doi: 10.1016/j.vaccine.2009.10.066. Epub 2009 Nov 1.

引用本文的文献

1
Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines.季节性灭活流感疫苗免疫后甲型流感病毒神经氨酸酶和血凝素抗体的纵向分析
Vaccines (Basel). 2023 Nov 20;11(11):1731. doi: 10.3390/vaccines11111731.

本文引用的文献

1
Characterization of Inactivated Influenza Vaccines Used in the Russian National Immunization Program.俄罗斯国家免疫规划中使用的灭活流感疫苗的特性
Vaccines (Basel). 2020 Aug 30;8(3):488. doi: 10.3390/vaccines8030488.
2
Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.流感神经氨酸酶：一种被忽视的蛋白质及其在更好流感疫苗方面的潜力。
Vaccines (Basel). 2020 Jul 23;8(3):409. doi: 10.3390/vaccines8030409.
3
Immune Response and Protective Efficacy of Inactivated and Live Influenza Vaccines Against Homologous and Heterosubtypic Challenge.
灭活和减毒流感疫苗针对同源和异源亚型攻击的免疫反应及保护效力
Biochemistry (Mosc). 2020 May;85(5):553-566. doi: 10.1134/S0006297920050041.
4
Better influenza vaccines: an industry perspective.更好的流感疫苗：行业视角。
J Biomed Sci. 2020 Feb 14;27(1):33. doi: 10.1186/s12929-020-0626-6.
5
Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement.比较不同检测方法和血凝抑制滴度测定的流感特异性中和抗体滴度：相关性良好，但一致性差。
Vaccine. 2020 Mar 4;38(11):2527-2541. doi: 10.1016/j.vaccine.2020.01.088. Epub 2020 Feb 7.
6
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.季节性流感疫苗预防和控制：免疫实践咨询委员会的建议 - 美国，2019-20 流感季。
MMWR Recomm Rep. 2019 Aug 23;68(3):1-21. doi: 10.15585/mmwr.rr6803a1.
7
Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.神经氨酸酶，被遗忘的表面抗原，作为流感疫苗靶点出现，以实现更广泛的保护。
J Infect Dis. 2019 Apr 8;219(Suppl_1):S75-S80. doi: 10.1093/infdis/jiz017.
8
Use of hexon as an antigen for the production of monoclonal antibodies capable of detecting multiple adenovirus types.使用六邻体作为抗原生产能够检测多种腺病毒类型的单克隆抗体。
Biologicals. 2019 Mar;58:44-49. doi: 10.1016/j.biologicals.2019.01.006. Epub 2019 Jan 17.
9
Influence of the Linking Order of Fragments of HA2 and M2e of the influenza A Virus to Flagellin on the Properties of Recombinant Proteins.甲型流感病毒HA2和M2e片段与鞭毛蛋白的连接顺序对重组蛋白性质的影响
Acta Naturae. 2018 Jan-Mar;10(1):85-94.
10
NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?神经氨酸酶为基础的免疫作用如何能有助于更好的流感病毒疫苗？
mBio. 2018 Apr 3;9(2):e02332-17. doi: 10.1128/mBio.02332-17.